Beclomethasone dipropionate plus VSL#3 for the treatment of mild to moderate diverticular colitis: An open, pilot study [3]

Journal of Clinical Gastroenterology

Volumn 39, Issue 7, 2005, Pages 644-646

  Tursi, Antonio ^a   Brandimarte, Giovanni ^b   Giorgetti, Gian Marco ^c   Elisei, Walter ^b  

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c Ospedale S Eugenic   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; PROBIOTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; COLITIS; DISEASE SEVERITY; DIVERTICULAR COLITIS; DIVERTICULOSIS; DRUG EFFICACY; ENDOSCOPY; FEMALE; HUMAN; LETTER; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RECURRENCE RISK; REMISSION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BECLOMETHASONE; DIVERTICULITIS, COLONIC; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 23044465319     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000170741.82004.70     Document Type: Letter

References (12)

1. West AB, Losada M. The pathology of diverticulosis coli. J Clin Gastroenterol. 2004;38(suppl. 1):11-16.
2. Cawthorn SJ, Gibbs NM, Marks CG. Segmental colitis: a complication of diverticular disease. Gut. 1983;24:A500.
3. Makapugay LM, Dean PJ. Diverticular disease-associated chronic colitis. Am J Surg Pathol. 1996;20:94-102.
4. Gore S, Sheperd ND, Wilkinson SP. Endoscopic crescent fold disease of the sigmoid colon: the clinical and histopathological spectrum of distinctive endoscopic appearance. Int J Colorectal Dis. 1992;7:76-81.
5. Banski G, Buhler H, Stamm B, et al. Treatment of distal ulcerative colitis with beclomethasone enemas: high therapeutic efficacy without endoscrine side-effects. A prospective, randomised, double-blind trial. Dis Colon Rectum. 1987;30:288-292.
6. Gionchetti P, Amadini C, Rizzello F, et al. Probiotics: role in inflammatory bowel disease. Dig Liver Dis. 2002;34(suppl 2):58-62.
7. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10:P1126-P1131.
8. Guslandi M. Segmental colitis: so what? Eur J Gastroenterol Hepatol. 2003;15:1-2.
9. Venturi A, Gionchetti P, Rizzello F, et al. Impact of the fecal flora composition by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108.
10. Hanauer SB. Medical therapy for ulcerative colitis. Gastroenterology. 2004;126:1582-1592.
11. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut. 1998;42:2-7.
12. Gionchetti P, Rizzello F, Cifone G, et al. In vivo effect of a highly concentrated probiotic on IL-10 pelvic pouch tissue levels [Abstract]. Gastroenterology. 1999;116:A723.